Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology

Maurizio Miano, Ugo Ramenghi, Giovanna Russo, Laura Rubert, Angelica Barone, Fabio Tucci, Piero Farruggia, Angelamaria Petrone, Anna Mondino, Laura Lo Valvo, Nicoletta Crescenzio, Francesco Bellia, Irene Olivieri, Elena Palmisani, Ilaria Caviglia, Carlo Dufour, Francesca Fioredda

Research output: Contribution to journalArticle

Abstract

Mycophenolate mofetil (MMF) has been shown to be effective in children with immune thrombocytopenia (ITP) and Evans syndrome (ES), but data from larger series and details on the timing of the response are lacking. We evaluated 56 children treated with MMF for ITP (n = 40) or ES (n = 16), which was primary or secondary to autoimmune lymphoproliferative syndrome -related syndrome (ARS). Thirty-five of the 54 evaluable patients (65%) achieved a partial (18%) or complete (46%) response after a median (range) of 20 (7-137) and 37 (7-192) d, respectively. ITP and ES patients responded in 58% and 81% of cases (P = not significant, ns), with complete response in 32% and 81% (P = 0·01), respectively. 60% and 73% of children with primary disease and ARS responded (P = ns) with complete response in 34% and 68% of cases (P = 0·01), respectively. Six of 35 (17%) children relapsed after a median of 283 d (range 189-1036). Limited toxicity was observed in four patients. The median durations of treatment and follow-up were seven and 12·7 months, respectively. This is the largest reported cohort of patients treated with MMF for ITP/ES. The results show that MMF is effective and safe and provides a relatively quick response, suggesting that it has a potential role as an alternative to more aggressive and expensive second/further-line treatments.

Original languageEnglish
Pages (from-to)490-495
Number of pages6
JournalBritish Journal of Haematology
Volume175
Issue number3
DOIs
Publication statusPublished - Nov 2016

Fingerprint

Mycophenolic Acid
Idiopathic Thrombocytopenic Purpura
Hematology
Thrombocytopenia
Pediatrics
Autoimmune Lymphoproliferative Syndrome
Therapeutics
Evans Syndrome

Keywords

  • Journal Article

Cite this

Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. / Miano, Maurizio; Ramenghi, Ugo; Russo, Giovanna; Rubert, Laura; Barone, Angelica; Tucci, Fabio; Farruggia, Piero; Petrone, Angelamaria; Mondino, Anna; Lo Valvo, Laura; Crescenzio, Nicoletta; Bellia, Francesco; Olivieri, Irene; Palmisani, Elena; Caviglia, Ilaria; Dufour, Carlo; Fioredda, Francesca.

In: British Journal of Haematology, Vol. 175, No. 3, 11.2016, p. 490-495.

Research output: Contribution to journalArticle

Miano, Maurizio ; Ramenghi, Ugo ; Russo, Giovanna ; Rubert, Laura ; Barone, Angelica ; Tucci, Fabio ; Farruggia, Piero ; Petrone, Angelamaria ; Mondino, Anna ; Lo Valvo, Laura ; Crescenzio, Nicoletta ; Bellia, Francesco ; Olivieri, Irene ; Palmisani, Elena ; Caviglia, Ilaria ; Dufour, Carlo ; Fioredda, Francesca. / Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. In: British Journal of Haematology. 2016 ; Vol. 175, No. 3. pp. 490-495.
@article{267a72eff21340df95886cbb46a97012,
title = "Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology",
abstract = "Mycophenolate mofetil (MMF) has been shown to be effective in children with immune thrombocytopenia (ITP) and Evans syndrome (ES), but data from larger series and details on the timing of the response are lacking. We evaluated 56 children treated with MMF for ITP (n = 40) or ES (n = 16), which was primary or secondary to autoimmune lymphoproliferative syndrome -related syndrome (ARS). Thirty-five of the 54 evaluable patients (65{\%}) achieved a partial (18{\%}) or complete (46{\%}) response after a median (range) of 20 (7-137) and 37 (7-192) d, respectively. ITP and ES patients responded in 58{\%} and 81{\%} of cases (P = not significant, ns), with complete response in 32{\%} and 81{\%} (P = 0·01), respectively. 60{\%} and 73{\%} of children with primary disease and ARS responded (P = ns) with complete response in 34{\%} and 68{\%} of cases (P = 0·01), respectively. Six of 35 (17{\%}) children relapsed after a median of 283 d (range 189-1036). Limited toxicity was observed in four patients. The median durations of treatment and follow-up were seven and 12·7 months, respectively. This is the largest reported cohort of patients treated with MMF for ITP/ES. The results show that MMF is effective and safe and provides a relatively quick response, suggesting that it has a potential role as an alternative to more aggressive and expensive second/further-line treatments.",
keywords = "Journal Article",
author = "Maurizio Miano and Ugo Ramenghi and Giovanna Russo and Laura Rubert and Angelica Barone and Fabio Tucci and Piero Farruggia and Angelamaria Petrone and Anna Mondino and {Lo Valvo}, Laura and Nicoletta Crescenzio and Francesco Bellia and Irene Olivieri and Elena Palmisani and Ilaria Caviglia and Carlo Dufour and Francesca Fioredda",
note = "{\circledC} 2016 John Wiley & Sons Ltd.",
year = "2016",
month = "11",
doi = "10.1111/bjh.14261",
language = "English",
volume = "175",
pages = "490--495",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology

AU - Miano, Maurizio

AU - Ramenghi, Ugo

AU - Russo, Giovanna

AU - Rubert, Laura

AU - Barone, Angelica

AU - Tucci, Fabio

AU - Farruggia, Piero

AU - Petrone, Angelamaria

AU - Mondino, Anna

AU - Lo Valvo, Laura

AU - Crescenzio, Nicoletta

AU - Bellia, Francesco

AU - Olivieri, Irene

AU - Palmisani, Elena

AU - Caviglia, Ilaria

AU - Dufour, Carlo

AU - Fioredda, Francesca

N1 - © 2016 John Wiley & Sons Ltd.

PY - 2016/11

Y1 - 2016/11

N2 - Mycophenolate mofetil (MMF) has been shown to be effective in children with immune thrombocytopenia (ITP) and Evans syndrome (ES), but data from larger series and details on the timing of the response are lacking. We evaluated 56 children treated with MMF for ITP (n = 40) or ES (n = 16), which was primary or secondary to autoimmune lymphoproliferative syndrome -related syndrome (ARS). Thirty-five of the 54 evaluable patients (65%) achieved a partial (18%) or complete (46%) response after a median (range) of 20 (7-137) and 37 (7-192) d, respectively. ITP and ES patients responded in 58% and 81% of cases (P = not significant, ns), with complete response in 32% and 81% (P = 0·01), respectively. 60% and 73% of children with primary disease and ARS responded (P = ns) with complete response in 34% and 68% of cases (P = 0·01), respectively. Six of 35 (17%) children relapsed after a median of 283 d (range 189-1036). Limited toxicity was observed in four patients. The median durations of treatment and follow-up were seven and 12·7 months, respectively. This is the largest reported cohort of patients treated with MMF for ITP/ES. The results show that MMF is effective and safe and provides a relatively quick response, suggesting that it has a potential role as an alternative to more aggressive and expensive second/further-line treatments.

AB - Mycophenolate mofetil (MMF) has been shown to be effective in children with immune thrombocytopenia (ITP) and Evans syndrome (ES), but data from larger series and details on the timing of the response are lacking. We evaluated 56 children treated with MMF for ITP (n = 40) or ES (n = 16), which was primary or secondary to autoimmune lymphoproliferative syndrome -related syndrome (ARS). Thirty-five of the 54 evaluable patients (65%) achieved a partial (18%) or complete (46%) response after a median (range) of 20 (7-137) and 37 (7-192) d, respectively. ITP and ES patients responded in 58% and 81% of cases (P = not significant, ns), with complete response in 32% and 81% (P = 0·01), respectively. 60% and 73% of children with primary disease and ARS responded (P = ns) with complete response in 34% and 68% of cases (P = 0·01), respectively. Six of 35 (17%) children relapsed after a median of 283 d (range 189-1036). Limited toxicity was observed in four patients. The median durations of treatment and follow-up were seven and 12·7 months, respectively. This is the largest reported cohort of patients treated with MMF for ITP/ES. The results show that MMF is effective and safe and provides a relatively quick response, suggesting that it has a potential role as an alternative to more aggressive and expensive second/further-line treatments.

KW - Journal Article

U2 - 10.1111/bjh.14261

DO - 10.1111/bjh.14261

M3 - Article

VL - 175

SP - 490

EP - 495

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -